Stockscreener 앱 받기
1.45
0.68%
-0.01
시간 외 거래:
1.48
0.03
+2.07%
Humacyte Inc 주식(HUMA)의 최신 뉴스
Investors who lost money on Humacyte, Inc.(HUMA) should contact Levi & Korsinsky about pending Class ActionHUMA - ACCESS Newswire
Humacyte, Inc. (NASDAQ:HUMA) Q4 2024 Earnings Call Transcript - Insider Monkey
Humacyte’s Earnings Call: Balancing Achievements and Challenges - TipRanks
Humacyte Stock (HUMA) Hits Record Low Post Q4 Results Despite FDA Nod for Vascular Trauma Treatment - markets.businessinsider.com
symbol__ Stock Quote Price and Forecast - CNN
Benchmark maintains Buy rating, $17 target on Humacyte stock By Investing.com - Investing.com UK
Humacyte, Inc. Class Action: Levi & Korsinsky Reminds Humacyte, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of January 17, 2025HUMA - ACCESS Newswire
Humacyte down following quarterly results, hits record low - MSN
Shareholders that lost money on Humacyte, Inc.(HUMA) should contact Levi & Korsinsky about pending Class ActionHUMA - ACCESS Newswire
Humacyte Stock Continues Slide Despite Lower Than Expected Q4 Loss – But Retail Gets More Bullish - MSN
Humacyte price target lowered to $8 from $10 at BTIG - Yahoo Finance
Humacyte’s Symvess Gains FDA Approval and Launches - TipRanks
Durham biotech defends lead product after concerns surface - The Business Journals
Humacyte shares tumble 10% as Q4 loss narrows but revenue remains elusive By Investing.com - Investing.com South Africa
Humacyte shares tumble 10% as Q4 loss narrows but revenue remains elusive - Investing.com India
Earnings call transcript: Humacyte Q4 2024 sees narrower EPS loss, stock edges up - Investing.com India
Humacyte Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Humacyte Announces Fourth Quarter and Year End 2024 Financial Results and Provides Business Update - Yahoo Finance
Humacyte responds to media coverage with SEC filing By Investing.com - Investing.com Australia
Humacyte CEO addresses concerns in NYT over FDA approval of Symvess - Investing.com
Humacyte responds to media coverage with SEC filing - Investing.com
Humacyte Defends Symvess Approval Amid FDA Scrutiny - TipRanks
Humacyte Earnings Preview - Benzinga
Durham biotech's stock price drops 30% amid offering, reports about product safety - The Business Journals
Brokers Suggest Investing in Humacyte, Inc. (HUMA): Read This Before Placing a Bet - MSN
Humacyte stock slides on pricing public offering of units to raise $50M - MSN
Humacyte Announces Public Offering to Raise $46.6 Million - TipRanks
Humacyte: Doubts Cast Around Efficacy Of Symvess May Be Hard To Dispel (NASDAQ:HUMA) - Seeking Alpha
Humacyte plunges after launching public offering of common stock - MSN
Wall Street Bulls Look Optimistic About Humacyte, Inc. (HUMA): Should You Buy? - MSN
Biggest stock movers Wednesday: GME, HUMA, DLTR, and more (HUMA:NASDAQ) - Seeking Alpha
FDA passes lab-grown blood vessel despite major concerns - Medical Brief
Why Humacyte (HUMA) Stock Is Falling Sharply - Benzinga
Humacyte to raise $50M; Acrivon to focus on prexasertib in endometrial cancer - Endpoints News
Humacyte to Present Fourth Quarter and Full Year Financial Results and Provide Corporate Update on March 28, 2025 - The Manila Times
Humacyte To Present Fourth Quarter And Full Year Financial Results And Provide Corporate Update On March 28, 2025 - MarketScreener
Humacyte stock plunges on public offering pricing By Investing.com - Investing.com South Africa
Major Biotech Innovation Updates Expected in Humacyte Q4 Earnings Call - Stock Titan
Humacyte stock plunges on public offering pricing - Investing.com
Dollar Tree, GameStop, Humacyte - TradingView
Humacyte tumbles on pricing $50 mln stock offering - TradingView
US Stocks Likely To Open Lower After 3-Day Advance: Market Is Looking 'More Balanced' And Gone From 'Above-Trend To On-Trend,' Says Expert - Benzinga
Humacyte Prices $50 Million Stock Offering - MarketScreener
Humacyte sets $2 stock offering, aims for $50 million By Investing.com - Investing.com South Africa
Humacyte Secures $50M Funding: Major Push for SYMVESS Commercialization - Stock Titan
Humacyte sets $2 stock offering, aims for $50 million - Investing.com
Humacyte, Inc. Announces Pricing of Public Offering of Common Stock - The Manila Times
Humacyte Prices Public Offering Of 25 Million Shares At $2.00 Per Share - Marketscreener.com
Humacyte announces public stock offering for expansion By Investing.com - Investing.com South Africa
1.23%
1.63%
자본화:
|
볼륨(24시간):